Logo
  • Home
  • Disease
  • Erdosteine
  • Countries
  • login

Erdosteine has been positively tested as Long COVID-19 treatment

Recipharm is pleased to announce that the results of a new study with erdosteine in "Long COVID-19" treatment are now available.

The study involved 38 COVID-19 post-discharged patients, divided into two groups: one taking erdosteine and one as control arm.

The study demonstrates that patients taking erdosteine 300 mg twice daily experience a significant greater improvement in respiratory symptoms and quality of life, compared to control arm. These outcomes confirm that erdosteine can be an effective treatment against persistent COVID-19 symptoms and can avoid the complications of Long COVID-19. Click here to access the new publication.

Erdosteine has been positively tested as part of COVID-19 treatment

Recipharm is pleased to announce that the results of the study with Erdosteine as add-on treatment for COVID-19 patients are now available.

The clinical study involved 20 patients affected by COVID-19 with severe respiratory failure, hospitalized in one of the major COVID-19 centres of Milan, in Lombardy, the Italian region most affected by SARS-CoV-2.

The study indicates that patients taking Erdosteine after hospital discharge benefits significant improvements in health-related quality of life parameters (HRQoL) and dyspnea. This study is one of the first to report HRQoL details in patients with COVID-19. Click here to access the publication.

Cough

Bronchitis

COPD

URTI-LRTI


© 2021 - Edmond Pharma S.r.l.
Società unipersonale - Soggetta alla direzione e coordinamento di Recipharm Italia S.p.A.
Legal address, administrative and production facility: Strada Statale dei Giovi, 131
20037 Paderno Dugnano (MI) P.iva IT 00804270155 - REA MI 780447